Is p53 expression, detected by immunohistochemistry, an important parameter of response to treatment in testis cancer?

Anticancer Research

Volumn 17, Issue 4 A, 1997, Pages 2663-2669

  Eid, Hanna ^a   Van Looij, Marco Der ^a   Institoris, Etel ^a   Géczi, Lajos ^a   Bodrogi, István ^a   Oláh, Edith ^a   Bak, Mihály ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

Author keywords

Chemoresistance,; Immunohistochemistry; p53 expression; Testis cancer

Indexed keywords

ANTINEOPLASTIC AGENT; GENE PRODUCT; MONOCLONAL ANTIBODY; PARAFFIN; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; DRUG SENSITIVITY; EMBRYONAL CARCINOMA; GENE EXPRESSION; GERM CELL TUMOR; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SEMINOMA; TESTIS CANCER; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; CARCINOMA, EMBRYONAL; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MUTATION; P-GLYCOPROTEIN; SEMINOMA; TESTICULAR NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030804718     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Finlay CA Hinds PW, Levine AJ: The P53 proto-oncogene can act as a suppressor of transformation. Cell 57: 1083-1093, 1989.
2. Lane DP, Benchimol S: P53 oncogene or anti-oncogene? Genes Develop 4: 1-8, 1990.
3. Louis DN: The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 53: 11-21, 1994.
4. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311, 1991.
5. Kastan BK, Zhan Q, El-deiry SW, Carrier F, Jacks T, Walsh VW, Plunkett SB, Vogelstein B, and Fornance JA: A mammalian cell cycle checkpoint pathway utiliting p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71: 587-597, 1992.
6. Callahan R: p53 mutations, another breast cancer prognostic factor. J Natl Cancer Inst 84: 826-827, 1992.
7. Lowe SW, Ruley HE, Jacks T and Houseman DE: p53-dependent apoptosis modulatges the cytotoxicity of anticancer agents. Cell 74: 957-968, 1993.
8. Rüther U, Nunnensiek C, Müller HAG, Bader H, Rupp W, Rothe B, Eisenberger F, Jipp P: Evidence of wild and mutant type p53 in human germ cell tumors by histochemical staining. Tumordiagn u Ther 73: 213-219, 1992.
9. Bartkova J, Bartek J, Lukás J, Vojtesek B, Stasková Z, Rejthar A, Kovarik J, Midgley CA and Lane D: P53 protein alterations in human testicular cancer including pre-invasive intratubular germ-cell neoplasia. Int J Cancer 49: 196-202, 1991.
10. Lewis DJ, Sesterheen IA, McCarthy WF, Moul JW: Immunohistochemical expression of P53 tumor suppressor gene protein in adult GCTT: clinical correlation in stage I disease. J Urol (USA) 152: 418-423, 1994.
11. Peng HO, Hogg D, Malkin D, Bailey, D, Gallie BL, Bulbul M, Jewett M, Buchanan J and Goss PE: Mutations of the p53 gene do not occur in testis cancer. Cancer Res 53: 3574-3578 1993.
12. Strohmeyer TG, Fleishhacker M, Imai Y, Slamon DJ, Koeffler HP: Status of the p53 tumor suppressor gene and the MDM-2 gene in human testicular tumors: J Urol, part 2, 149: 311 A, abstract 393, 1993.
13. Wei DY, Jiafu Z, Xi SQ, Yongjiang M, Xiulong Z, Daizong L, and Jianren G: p53 gene mutation in Chinese human testicular seminoma. J Urology 150: 884-886, 1993.
14. International Union Against Cancer (UICC): TNM classification of malignant tumours. 4th. Fully rev. ed. New York: Springer-Verlag 1987.
15. Javadpour N: The role of biologic tumor markers in testicular cancer. Cancer 45: (Suppl): 1755-1761, 1980.
16. Mostofi FK, Sesterhenn IA and Davis CJ: World health organisation international histological classification of germ-cell tumours of the testis. In: Jones WG, Ward MA, and Anderson CK (eds.), Germ-cell tumours, II, 1 23, Pergamon, Oxford, 1986.
17. Cattoretti G, Becker GM, Key G, Duchrow M, Schlüter C, Gall J, Gerd J: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIBI and MIB3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathology 168: 357-363, 1992.
18. Hall PA and Lane DP: p53 in tumour pathology: can we trus immunohistochemistry? -Revisited. J of Pathology 172: 1-4, 1994.
19. Lipponen PK: Over-expression of p53 nuclear oncoprotein in transitional- cell bladder cancer and its prognostic value. Int J Cancer 53: 465-470, 1993.
20. Monfardini S, Brunner K, Crowther D, Olive D, MacDonald J, Eckhardt S et al: Manual of Cancer Chemotherapy, Third edition, UICC Technical Report Series 56: Geneva 1981.
21. Lambkin HA, Mothersill CM, Kelehan P: Variations in immunohistochemical detection of p53 protein over-expression in cervical tumours with different antibodies and methods of detection. J Pathol 172: 13-18, 1994.
22. Shuin T, Misaki H, Kubata Y, Yao M, and Hosaka M: Differential expression of protooncogenes in human germ cell tumors of the testis. Cancer 73: 1721-1727, 1994.
23. Chin KV, Ueda K, Pastan I, Gottesman MM: Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science 255: 459-462, 1992.
24. Lin J, Wu X, Chen J, Chang A, Levine AJ: Functions of the p53 protein in growth regulation and tumor suppression. Cold Spring Harbor Symposia on Quantitative Biology, LIX. The Molecular Genetics of Cancer. Plainview, Cold Spring Harbor Laboratory Press 215-223, 1994.
25. Nguyen KT, Liu B, Ueda K, Gottesman MM, Pastan I, Chin KV: Transactivation of the human multidrug resistance (MDR) gene promoter by p53 mutants. Oncol Res 6: 71-77, 1994.
26. Wosikowski K, Regis JT, Rebey RW: Normal p53 status and function despite the development of drug resistance in human breast cancer cells. Cell Growth and Differ 6: 1395-1403, 1995.
27. Goldsmith ME, Gudas JM, Schneider E, Cowan KH: Wild type p53 stimulates expression from the human multidrug resistance promoter in p53-negative cell line. J Biol Chem 270: 1894-1898, 1995.
28. Eid H, Bodrogi I, Csókay B, Oláh E, Bak M: Multidrug resistance of testis cancers: the study of clinical relevance of P-glycoprotein expression. Anticancer Res 6: 3447-3452, 1996.
29. Rubio MP, von Deimling A, Yandett DW, Wiestler OD, Gusella JF, Louis DM: Accumulation of wild-type p53 in human astrocytomas. Cancer Res 53: 3465-3467, 1993.
30. El Rouby S, Thomas A, Costin D, et al: p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82: 3452-3459, 1993.
31. Preudhomme C, Lepelley, Vachee A, Soenen V, Quesnel B, Cosson A, Fenaux P: Relationship between p53 gene mutations and multidrug resistance (MDR1) gene expression in myelodysplastic syndromes. Leukemia 7: 1888-1890, 1993.
32. Schneider J, Rubio MP, Barbazan MJ, Rodriguez-Escudero FJ, Seiznger BR, Castresana JS: P-glycoprotein, Her-2/neu, and mutant p53 expression in human gynecologic tumors. J Natl Cancer Inst 86: 850-855, 1994.
33. De Angelis P, Stokke T, Smedshammer L, Lother RA, Lehne G, Chen Y, Clausen OFF: P-glycoprotein is not expressed in a majority of colorectal carcinomas and is not regulated by mutant p53 in vivo. Br J Cancer 72: 307-311, 1995.
34. Kant Ed, Heide I, Thiede C, Herrmann R, Rochlitz FC: MDRI expression correlates with mutant p53 expression in colorectal cancer metastases. J Cancer Res Clin Oncol 122: 671-675, 1996.
35. Kuczyk AM, Serth J Bokemeyer C, Allhoff EP, Jonassen J, Kuczyk S, Jonas U P53 mutant gene expression in archival material of mature teratoma of the testis. Path Res Pract 190: 993-998, 1994.
36. Van Der Looij M, Eid H, Bak M, Bodrogi I, Oláh E: Allele loss of tumor suppressor genes on chromosome 17 in Human testicular germ cell tumors: Int J Oncol 9: 1087-1090, 1996
37. Smith ML, Chen I, Zhan Q, O'Connor PM, Fornace AJ, Jr: Involvement of the p53 tumor suppressor in repair of UV-type DNA damage. Oncogene, in press, 1995.
38. Fan S, Smith ML, Rivet II DJ, Duba D, Zhan Q, Kohn KW, Fornace AJ, and O, Connor PM: Disruption of p53 function sensitizes breast cancer MCF-7 cells to Cisplatin and l'entoxifylline. Cancer Res 55: 1649-1654, 1995.
39. Hawking SD, Demers WG, Galloway AD: Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56: 15, 892-898, 1996.
40. Passlick B, Izbicki JR, Riethmuller G, Pantel K: P53 in non-small-cell lung cancer (letter). J Natl Cancer Inst 86: 801-802, 1994.
41. Volm M, J Mattern: Immunohistochemical detection of p53 in non-small-cell lung cancer (letter). J Nat Cancer Inst 86: 1249, 1994.
42. Soo Lee J, Yoon A, Kalapurakal KS, Ro YJ, Lee J, Tu N, Hittelman NV, Hong KW: Expression of p53 oncoprotein in Non-Small-Cell Lung Cancer. J Clin Oncol 13: 1893-1903, 1995.
43. Kyritsis PA, Bondy LM, Hess RK, Cunningham EJ, Zhu D, Amos JC, Jung AKW, Levin AV, Bruner MJ: Prognostic significance of p53 immunoreactivity in patients with glioma. Clin Cancer Res 1: 1617-1622, 1995.